Successful Use of Apremilast in Psoriasiform Dermatitis Refractory to Biologics

Christopher S. Yang*, Victor Quan, Ahmad Amin

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Psoriasis is a common immune-mediated disease that can affect the skin, nails, and joints. Management is usually comprised of topical therapy and/or systemic therapy, either biologic or nonbiologic. This case shows a psoriasiform dermatitis with primary response failure to several systemic biologic and nonbiologic therapies for atopic dermatitis (methotrexate, dupilumab) and psoriasis (cyclosporine, adalimumab, ustekinumab, guselkumab, ixekizumab). Ultimately, the patient was treated successfully with apremilast. This case suggests that certain cases of psoriasis may improve exclusively with PDE-4 inhibition. Conversely, this could also suggest existence of a separate entity of psoriasiform dermatitis that is primarily mediated by PDE-4. We encourage a trial of apremilast in patients presenting with disease mimicking psoriasis who fail multiple therapies.

Original languageEnglish (US)
Pages (from-to)693-696
Number of pages4
JournalSKIN: Journal of Cutaneous Medicine
Volume5
Issue number6
DOIs
StatePublished - 2021

Keywords

  • adalimumab
  • apremilast
  • atopic dermatitis
  • biologics
  • cyclosporine
  • dupilumab
  • guselkumab
  • ixekizumab
  • methotrexate
  • phosphodiesterase-4
  • psoriasiform dermatitis
  • psoriasis
  • ustekinumab

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Successful Use of Apremilast in Psoriasiform Dermatitis Refractory to Biologics'. Together they form a unique fingerprint.

Cite this